ARQT vs DERM vs SKIN vs NVCR vs INVA

For growth investors, Arcutis Biotherapeutics, Inc.

(ARQT) is the stronger pick with 91. 3% revenue growth year-over-year, versus -29. 1% for Journey Medical Corporation (DERM). Innoviva, Inc. (INVA) offers the better valuation at 6. 9x trailing P/E (11. 9x forward), making it the more compelling value choice. Analysts rate Arcutis Biotherapeutics, Inc. (ARQT) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Innoviva, Inc.

is actually cheaper at 11. 9x.

Over the past 5 years, Innoviva, Inc.

(INVA) delivered a total return of +94. 4%, compared to -92. 9% for The Beauty Health Company (SKIN). Over 10 years, the gap is even starker: INVA returned +94. 9% versus SKIN's -91. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Innoviva, Inc.

(INVA) is the lower-risk stock at 0. 13β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 1648% more volatile than INVA relative to the S&P 500. On balance sheet safety, Arcutis Biotherapeutics, Inc. (ARQT) carries a lower debt/equity ratio of 3% versus 6% for The Beauty Health Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Arcutis Biotherapeutics, Inc.

(ARQT) is pulling ahead at 91. 3% versus -29. 1% for Journey Medical Corporation (DERM). On earnings-per-share growth, the picture is similar: Innoviva, Inc. grew EPS 816. 7% year-over-year, compared to -242. 9% for Journey Medical Corporation. Over a 3-year CAGR, ARQT leads at 367. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Innoviva, Inc.

(INVA) is the more profitable company, earning 63. 8% net margin versus -26. 1% for Journey Medical Corporation — meaning it keeps 63. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INVA leads at 38. 5% versus -24. 4% for DERM. At the gross margin level — before operating expenses — ARQT leads at 90. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Innoviva, Inc.

(INVA) trades at 11. 9x forward P/E versus 77. 6x for Arcutis Biotherapeutics, Inc. — 65. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DERM: 135. 0% to $11. 75.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Innoviva, Inc.

(INVA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 13)). The Beauty Health Company (SKIN) carries a higher beta of 2. 00 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (INVA: +94. 9%, SKIN: -91. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ARQT (Healthcare) and DERM (Healthcare) and SKIN (Consumer Defensive) and NVCR (Healthcare) and INVA (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ARQT is a small-cap high-growth stock; DERM is a small-cap quality compounder stock; SKIN is a small-cap quality compounder stock; NVCR is a small-cap quality compounder stock; INVA is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.